Singulair joins the fray
This article was originally published in The Tan Sheet
Executive Summary
Asthma drug Singulair (montelukast sodium) receives FDA approval for seasonal allergic rhinitis (hay fever) indication Dec. 31, Merck says. Available by prescription in 10 mg tablets for adults, 4 mg and 5 mg chewable tablets for children two to 14, as well as 4 mg oral granules, the product joins the dynamic allergy relief market now adjusting to OTC availability of loratadine (Claritin, Alavert). Merck says it currently has no plans to switch Singulair OTC...